424 related articles for article (PubMed ID: 29250791)
41. Factors associated with persistence of red blood cell antibodies in woman after pregnancies complicated by fetal alloimmune haemolytic disease treated with intrauterine transfusions.
Verduin EP; Brand A; van de Watering LM; Claas FH; Oepkes D; Lopriore E; Doxiadis II; Schonewille H
Br J Haematol; 2015 Feb; 168(3):443-51. PubMed ID: 25244566
[TBL] [Abstract][Full Text] [Related]
42. Absence of hemolytic disease of fetus and newborn despite maternal high-titer IgG anti-Ku.
Kakaiya RM; Whaley A; Howard-Menk C; Rami J; Papari M; Campbell-Lee S; Malecki Z
Immunohematology; 2010; 26(3):119-23. PubMed ID: 21214298
[TBL] [Abstract][Full Text] [Related]
43. Maternal red blood cell alloimmunization requiring intrauterine transfusion: a comparative study on management and outcome depending on the type of antibody.
Phung TV; Houfflin-Debarge V; Ramdane N; Ghesquière L; Delsalle A; Coulon C; Subtil D; Vaast P; Garabedian C
Transfusion; 2018 May; 58(5):1199-1205. PubMed ID: 29512164
[TBL] [Abstract][Full Text] [Related]
44. Hemolytic disease of the fetus and newborn owing to anti-U, successfully treated with repeated intrauterine transfusions.
Strindberg J; Lundahl J; Ajne G
Immunohematology; 2013; 29(2):51-4. PubMed ID: 24094236
[TBL] [Abstract][Full Text] [Related]
45. Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study.
Delaney M; Wikman A; van de Watering L; Schonewille H; Verdoes JP; Emery SP; Murphy MF; Staves J; Flach S; Arnold DM; Kaufman RM; Ziman A; Harm SK; Fung M; Eppes CS; Dunbar NM; Buser A; Meyer E; Savoia H; Abeysinghe P; Heddle N; Tinmouth A; Traore AN; Yazer MH;
Transfusion; 2017 Mar; 57(3):525-532. PubMed ID: 28164304
[TBL] [Abstract][Full Text] [Related]
46. Intravenous fetal exchange transfusion before 22 weeks of gestation in early and severe red-cell fetomaternal alloimmunization.
Poissonnier MH; Picone O; Brossard Y; Lepercq J
Fetal Diagn Ther; 2003; 18(6):467-71. PubMed ID: 14564122
[TBL] [Abstract][Full Text] [Related]
47. History and current standard of postnatal management in hemolytic disease of the fetus and newborn.
De Winter DP; Hulzebos C; Van 't Oever RM; De Haas M; Verweij EJ; Lopriore E
Eur J Pediatr; 2023 Feb; 182(2):489-500. PubMed ID: 36469119
[TBL] [Abstract][Full Text] [Related]
48. [Management of feto-maternal red cell allo-immunizations].
Bricca P; Guinchard E; Guitton Bliem C
Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
[TBL] [Abstract][Full Text] [Related]
49. Neonatal outcome after fetal anemia managed by intrauterine transfusion.
Garabedian C; Rakza T; Thomas D; Wibaut B; Vaast P; Subtil D; Houfflin-Debarge V
Eur J Pediatr; 2015 Nov; 174(11):1535-9. PubMed ID: 26032762
[TBL] [Abstract][Full Text] [Related]
50. Impact of intrauterine transfusion on fetal coagulation physiology by thromboelastography.
Emery SP; Lopa S; Waters JH
Prenat Diagn; 2020 Apr; 40(5):585-589. PubMed ID: 31994748
[TBL] [Abstract][Full Text] [Related]
51. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
[TBL] [Abstract][Full Text] [Related]
52. Severity of haemolytic disease of the fetus and newborn in patients with a history of intrauterine transfusions in a previous pregnancy: A nationwide retrospective cohort study.
Van't Oever RM; Zwiers C; de Haas M; le Cessie S; Lopriore E; Oepkes D; Verweij EJTJ
BJOG; 2024 May; 131(6):769-776. PubMed ID: 37743689
[TBL] [Abstract][Full Text] [Related]
53. Serial blood donations for intrauterine transfusions of severe hemolytic disease of the newborn with the use of recombinant erythropoietin in a pregnant woman alloimmunized with anti-Ku.
Lydaki E; Nikoloudi I; Kaminopetros P; Bolonaki I; Sifakis S; Kikidi K; Koumantakis E; Foundouli K
Transfusion; 2005 Nov; 45(11):1791-5. PubMed ID: 16271105
[TBL] [Abstract][Full Text] [Related]
54. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations.
Hendrickson JE; Delaney M
Transfus Med Rev; 2016 Oct; 30(4):159-64. PubMed ID: 27397673
[TBL] [Abstract][Full Text] [Related]
55. Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation.
Schonewille H; Prinsen-Zander KJ; Reijnart M; van de Watering L; Zwaginga JJ; Meerman RH; van Kamp IL; Brand A
Transfusion; 2015 Dec; 55(12):2912-9; quiz 2911. PubMed ID: 26173835
[TBL] [Abstract][Full Text] [Related]
56. Intrauterine transfusion and non-invasive treatment options for hemolytic disease of the fetus and newborn - review on current management and outcome.
Zwiers C; van Kamp I; Oepkes D; Lopriore E
Expert Rev Hematol; 2017 Apr; 10(4):337-344. PubMed ID: 28277805
[TBL] [Abstract][Full Text] [Related]
57. Red Blood Cell Alloimmunization in the Pregnant Patient.
Webb J; Delaney M
Transfus Med Rev; 2018 Oct; 32(4):213-219. PubMed ID: 30097223
[TBL] [Abstract][Full Text] [Related]
58. Predicting Intrauterine Transfusion Interval and Perinatal Outcomes in Alloimmunized Pregnancies: Time-to-Event Survival Analysis.
Snelgrove JW; D'Souza R; Seaward PGR; Windrim R; Kelly EN; Ryan G
Fetal Diagn Ther; 2019; 46(6):425-432. PubMed ID: 31195389
[TBL] [Abstract][Full Text] [Related]
59. Successful use of maternal blood in the management of severe hemolytic disease of the fetus and newborn due to anti-Kp(b).
Bleile MJ; Rijhsinghani A; Dwyre DM; Raife TJ
Transfus Apher Sci; 2010 Dec; 43(3):281-283. PubMed ID: 20951648
[TBL] [Abstract][Full Text] [Related]
60. Persistence of Villous Immaturity in Term Deliveries Following Intrauterine Transfusion for Parvovirus B19 Infection and RhD-associated Hemolytic Disease of the Fetus and Newborn.
McCarthy WA; Popek EJ
Pediatr Dev Pathol; 2017; 20(6):469-474. PubMed ID: 29187036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
